INS and metabolic dysfunction-associated steatotic liver disease: Current study showed that anti-diabetic agents, glucagon-like peptide-1 modulators, sodium-glucose transport protein inhibitors, and thiazolidinedione insulin sensitizers can be potentially used to NAFLD medicine [6].